FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912017753> ?p ?o ?g. }

• W2912017753 endingPage "891" @default.
• W2912017753 startingPage "878" @default.
• W2912017753 abstract "Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial was undertaken to evaluate the efficacy, including inhibition of structural progression, and safety of tofacitinib in patients with active RA and an inadequate response to methotrexate (MTX). Month 24 data from the completed study are reported here.Patients were randomized 4:4:1:1 to receive tofacitinib 5 mg or 10 mg twice daily, or placebo, switched to tofacitinib 5 mg or 10 mg twice daily, with stable background MTX. Patients receiving placebo switched to tofacitinib at month 3 (nonresponders) or month 6 (remaining patients). Clinical efficacy, structural progression, and treatment-emergent adverse events were evaluated. Analyses were performed on the full analysis set with observed data or nonresponder imputation with no advancement penalty for clinical efficacy, and imputation by linear extrapolation for structural progression.Overall, 797 patients were treated; 539 (67.6%) completed 24 months of treatment. Responses according to the American College of Rheumatology criteria for 20% improvement (ACR20), ACR50, and ACR70; the proportion of patients in whom remission or low disease activity was achieved according to the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate, Clinical Disease Activity Index, or Simplified Disease Activity Index; Boolean remission; and Health Assessment Questionnaire disability index scores were maintained from month 12 to 24 and were similar between tofacitinib dosages. Limited structural damage was observed at months 12 and 24. Safety events were similar in type and frequency for both tofacitinib dosages, and were consistent with those previously reported.Our findings indicate that clinical and radiographic treatment effects are sustained in months 12-24 in patients with RA receiving tofacitinib 5 mg or 10 mg twice daily plus MTX. The safety profile is consistent with that of other tofacitinib studies." @default.
• W2912017753 created "2019-02-21" @default.
• W2912017753 creator A5006565253 @default.
• W2912017753 creator A5009838045 @default.
• W2912017753 creator A5011826741 @default.
• W2912017753 creator A5012283576 @default.
• W2912017753 creator A5013851404 @default.
• W2912017753 creator A5014147030 @default.
• W2912017753 creator A5015953107 @default.
• W2912017753 creator A5036051895 @default.
• W2912017753 creator A5040449706 @default.
• W2912017753 creator A5046261111 @default.
• W2912017753 creator A5056553996 @default.
• W2912017753 creator A5057538503 @default.
• W2912017753 creator A5064863811 @default.
• W2912017753 creator A5080646462 @default.
• W2912017753 creator A5089158758 @default.
• W2912017753 creator A5091416598 @default.
• W2912017753 date "2019-04-24" @default.
• W2912017753 modified "2023-10-17" @default.
• W2912017753 title "Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase <scp>III</scp> Study" @default.
• W2912017753 cites W1925361523 @default.
• W2912017753 cites W2014330392 @default.
• W2912017753 cites W2035320881 @default.
• W2912017753 cites W2046744512 @default.
• W2912017753 cites W2069302785 @default.
• W2912017753 cites W2099334955 @default.
• W2912017753 cites W2110177517 @default.
• W2912017753 cites W2139323151 @default.
• W2912017753 cites W2149447280 @default.
• W2912017753 cites W2153414586 @default.
• W2912017753 cites W2157885750 @default.
• W2912017753 cites W2158830347 @default.
• W2912017753 cites W2159106700 @default.
• W2912017753 cites W2163184895 @default.
• W2912017753 cites W2164858045 @default.
• W2912017753 cites W2265836205 @default.
• W2912017753 cites W2344174939 @default.
• W2912017753 cites W2584430503 @default.
• W2912017753 cites W2793417132 @default.
• W2912017753 cites W4249063051 @default.
• W2912017753 doi "https://doi.org/10.1002/art.40803" @default.
• W2912017753 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6593705" @default.
• W2912017753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30666826" @default.
• W2912017753 hasPublicationYear "2019" @default.
• W2912017753 type Work @default.
• W2912017753 sameAs 2912017753 @default.
• W2912017753 citedByCount "57" @default.
• W2912017753 countsByYear W29120177532019 @default.
• W2912017753 countsByYear W29120177532020 @default.
• W2912017753 countsByYear W29120177532021 @default.
• W2912017753 countsByYear W29120177532022 @default.
• W2912017753 countsByYear W29120177532023 @default.
• W2912017753 crossrefType "journal-article" @default.
• W2912017753 hasAuthorship W2912017753A5006565253 @default.
• W2912017753 hasAuthorship W2912017753A5009838045 @default.
• W2912017753 hasAuthorship W2912017753A5011826741 @default.
• W2912017753 hasAuthorship W2912017753A5012283576 @default.
• W2912017753 hasAuthorship W2912017753A5013851404 @default.
• W2912017753 hasAuthorship W2912017753A5014147030 @default.
• W2912017753 hasAuthorship W2912017753A5015953107 @default.
• W2912017753 hasAuthorship W2912017753A5036051895 @default.
• W2912017753 hasAuthorship W2912017753A5040449706 @default.
• W2912017753 hasAuthorship W2912017753A5046261111 @default.
• W2912017753 hasAuthorship W2912017753A5056553996 @default.
• W2912017753 hasAuthorship W2912017753A5057538503 @default.
• W2912017753 hasAuthorship W2912017753A5064863811 @default.
• W2912017753 hasAuthorship W2912017753A5080646462 @default.
• W2912017753 hasAuthorship W2912017753A5089158758 @default.
• W2912017753 hasAuthorship W2912017753A5091416598 @default.
• W2912017753 hasBestOaLocation W29120177531 @default.
• W2912017753 hasConcept C126322002 @default.
• W2912017753 hasConcept C141071460 @default.
• W2912017753 hasConcept C142724271 @default.
• W2912017753 hasConcept C168563851 @default.
• W2912017753 hasConcept C1862650 @default.
• W2912017753 hasConcept C197934379 @default.
• W2912017753 hasConcept C198451711 @default.
• W2912017753 hasConcept C204787440 @default.
• W2912017753 hasConcept C27081682 @default.
• W2912017753 hasConcept C2777575956 @default.
• W2912017753 hasConcept C2778143017 @default.
• W2912017753 hasConcept C2778886723 @default.
• W2912017753 hasConcept C2781059491 @default.
• W2912017753 hasConcept C71924100 @default.
• W2912017753 hasConceptScore W2912017753C126322002 @default.
• W2912017753 hasConceptScore W2912017753C141071460 @default.
• W2912017753 hasConceptScore W2912017753C142724271 @default.
• W2912017753 hasConceptScore W2912017753C168563851 @default.
• W2912017753 hasConceptScore W2912017753C1862650 @default.
• W2912017753 hasConceptScore W2912017753C197934379 @default.
• W2912017753 hasConceptScore W2912017753C198451711 @default.
• W2912017753 hasConceptScore W2912017753C204787440 @default.
• W2912017753 hasConceptScore W2912017753C27081682 @default.
• W2912017753 hasConceptScore W2912017753C2777575956 @default.
• W2912017753 hasConceptScore W2912017753C2778143017 @default.
• W2912017753 hasConceptScore W2912017753C2778886723 @default.
• W2912017753 hasConceptScore W2912017753C2781059491 @default.

• next